Science Explorer Interactive view Map
Company · Newton · United States

Karyopharm Therapeutics (United States)

In research, Karyopharm Therapeutics (United States) stands highest in Life Sciences (#12,220 of 14,347 worldwide), over all time.

karyopharm.comROR OpenAlex
World rank, all time
#31,461
of 42,892
Rank in United States
#6,721
of 8,685
Research works
227
▼ 19% vs 2013–17
Citations
3.9k
17.2 per fractional work
Top-10% rate
12.8%
record average 16.5%
Open access
34%
world 28%

What is Karyopharm Therapeutics (United States) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Life SciencesDomain #12,220 of 14,347 14.4%121

Each strip is that field’s whole ranked pool, with the notch where Karyopharm Therapeutics (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 7.46× its world share, 15 worksBiochemistry, Geneti…Immunology and Microbiology: 2.67× its world share, 1 worksImmunology and Micro…Neuroscience: 0.81× its world share, 0 worksNeuroscienceChemistry: 0.10× its world share, 0 worksChemistryComputer Science: 0.03× its world share, 0 worksComputer ScienceMaterials Science: 0.06× its world share, 0 worksMaterials ScienceMathematics: 0.25× its world share, 0 worksMathematicsHealth Professions: 0.10× its world share, 0 worksHealth ProfessionsMedicine: 2.79× its world share, 20 worksMedicineNursing: 0.65× its world share, 0 worksNursingVeterinary: 1.32× its world share, 0 worksVeterinaryArts and Humanities: 0.10× its world share, 0 worksArts and HumanitiesEconomics, Econometrics and Finance: 0.14× its world share, 0 worksEconomics, Econometr…Psychology: 0.13× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 7.5×. Every wedge is a field page.

Who are the top researchers at Karyopharm Therapeutics (United States)?

Ranked on the composite score, Margaret Lee, Boris Klebanov and William Senapedis lead among researchers whose main affiliation is Karyopharm Therapeutics (United States).

  1. 1 Margaret Lee United States · #196,802 worldwide 203 citations · 18 works
  2. 2 Boris Klebanov United States · #295,398 worldwide 72 citations · 18 works
  3. 3 William Senapedis United States · #510,455 worldwide 86 citations · 28 works
  4. 4 Erkan Baloglu United States · #525,322 worldwide 85 citations · 30 works
  5. 5 Michael Kauffman United States · #547,712 worldwide 129 citations · 52 works
  6. 6 Sharon Shacham United States · #579,068 worldwide 142 citations · 61 works
  7. 7 Yosef Landesman United States · #864,733 worldwide 92 citations · 38 works
  8. 8 Robert Carlson United States · #951,627 worldwide 41 citations · 40 works
  9. 9 Trinayan Kashyap United States · #1,188,493 worldwide 25 citations · 18 works
All ranked researchers at Karyopharm Therapeutics (United States)

Which keywords describe research at Karyopharm Therapeutics (United States)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Cell Cycle, Nuclear Pore Complex, Nucleocytoplasmic Transport, Proteasome Inhibitors, Minimal Residual Disease, Cancer, Staging System and Diagnosis Criteria.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cell Cycle4▲ 342×2 topics
  2. Nuclear Pore Complex3▲ 906×1 topic
  3. Nucleocytoplasmic Transport3▲ 906×1 topic
  4. Proteasome Inhibitors3▲ 131×2 topics
  5. Cancer3▲ 6.4×12 topics
  6. Minimal Residual Disease3▲ 117×2 topics
  7. Diagnosis Criteria3▲ 220×1 topic
  8. International Myeloma Working Group3▲ 220×1 topic
  9. Prognostic Factors3▲ 18×5 topics
  10. Staging System3▲ 128×2 topics
  11. Oxidative Stress3▲ 4.5×8 topics
  12. Immunotherapy3▲ 9.8×9 topics
  13. Hematopoietic Stem Cells2▲ 77×3 topics
  14. Mutation2▲ 33×2 topics
  15. AML2▲ 120×1 topic
  16. Acute Myeloid Leukemia2▲ 120×1 topic
  17. Cancer Therapy2▲ 9.5×7 topics
  18. Tumor Microenvironment2▲ 12×6 topics
  19. JAK2 Mutation2▲ 220×1 topic
  20. Myelofibrosis2▲ 220×1 topic
  21. Cholesterol2▲ 33×2 topics
  22. Cognitive Function2▲ 25×3 topics
  23. Fatty Acid Synthase2▲ 114×1 topic
  24. Lipid Metabolism2▲ 114×1 topic
  25. Transcriptional Regulation2▲ 28×3 topics
  26. Antiepileptic Drugs2▲ 57×1 topic
  27. BCR-ABL2▲ 162×1 topic
  28. Imatinib2▲ 162×1 topic
  29. Neurodevelopmental Disorders2▲ 33×2 topics
  30. Prenatal Exposure2▲ 143×1 topic
  31. BET Bromodomains1▲ 126×1 topic
  32. Metabolic Regulation1▲ 21×2 topics
  33. Nuclear Receptors1▲ 39×3 topics
  34. PROTACs1▲ 126×1 topic
  35. Inflammation1▲ 1.59×12 topics
  36. Tumor Regression1▲ 29×2 topics
  37. Apoptosis1▲ 9.3×4 topics
  38. HIF-11▲ 52×1 topic
  39. Regulation1▲ 5.5×3 topics
  40. Warburg Effect1▲ 52×1 topic

Which research topics does Karyopharm Therapeutics (United States) publish most on?

By volume in 2022–2025: Nuclear Structure and Function, Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research and Myeloproliferative Neoplasms: Diagnosis and Treatment.

Nuclear Structure and Function: 3 fractional worksMultiple Myeloma Research and Treatments: 3 fractional worksAcute Myeloid Leukemia R…2Acute Myeloid Leukemia Research: 2 fractional worksMyeloproliferative Neopl…2Myeloproliferative Neoplasms: Diagnosis and Treatment: 2 fractional worksCancer, Lipids, and Metabolism: 2 fractional worksPharmacological Effects and Toxicity Studies: 2 fractional worksChronic Myeloid Leukemia…2Chronic Myeloid Leukemia Treatments: 2 fractional worksProtein Degradation and Inhibitors: 1 fractional worksCancer, Hypoxia, and Metabolism: 1 fractional worksDrug Transport and Resistance Mechanisms: 1 fractional works
Molecular BiologyHematologyGeneticsCancer Research2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Nuclear Structure and Function Molecular Biology 3 works
  2. 2 Multiple Myeloma Research and Treatments Hematology 3 works
  3. 3 Acute Myeloid Leukemia Research Hematology 2 works
  4. 4 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 2 works
  5. 5 Cancer, Lipids, and Metabolism Cancer Research 2 works
  6. 6 Pharmacological Effects and Toxicity Studies Pediatrics, Perinatology and Child Health 2 works
  7. 7 Chronic Myeloid Leukemia Treatments Hematology 2 works
  8. 8 Protein Degradation and Inhibitors Molecular Biology 1 works
  9. 9 Cancer, Hypoxia, and Metabolism Cancer Research 1 works
  10. 10 Drug Transport and Resistance Mechanisms Oncology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available34.5%not open65.5%

World: 28% of research is openly available.

with international co-authors24.7%domestic only75.3%

World: 19% is written across borders.

How has Karyopharm Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 19% lower than in 2013–2017.

20152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Newton

All research institutions in Newton

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.